A W Mangel

Summary

Affiliation: RTI International
Country: USA

Publications

  1. pmc Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
    Allen W Mangel
    RTI Health Solutions, Research Triangle Park, NC
    Clin Exp Gastroenterol 5:1-10. 2012
  2. pmc Depolarization-stimulated contractility of gastrointestinal smooth muscle in calcium-free solution: a review
    Emily D Evans
    RTI Health Solutions, 3040 Cornwallis Drive, Research Triangle Park, NC 27709, USA
    ISRN Gastroenterol 2011:692528. 2011
  3. ncbi request reprint Clinical trials in irritable bowel syndrome: a review
    Claire M Ervin
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Rev Recent Clin Trials 8:9-22. 2013
  4. doi request reprint Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome
    A W Mangel
    RTI Health Solutions, Research Triangle Park, NC, USA
    Aliment Pharmacol Ther 28:239-49. 2008
  5. doi request reprint Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients
    Allen W Mangel
    RTI Health Solutions, Research Triangle Park, N C 27709, USA
    Digestion 78:180-6. 2008
  6. doi request reprint Asimadoline in the treatment of irritable bowel syndrome
    Allen W Mangel
    RTI Health Solutions NC 27709, USA
    Expert Opin Investig Drugs 19:1257-64. 2010
  7. ncbi request reprint Personal view: adequate relief as a primary endpoint in irritable bowel syndrome
    A W Mangel
    Research Triangle Institute Health Solutions, Research Triangle Park, NC 27709, USA
    Aliment Pharmacol Ther 23:879-81. 2006
  8. doi request reprint Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists
    A W Mangel
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Neurogastroenterol Motil 20:1086-93. 2008
  9. ncbi request reprint Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome
    R E Williams
    Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC 27709 3395, USA
    Aliment Pharmacol Ther 23:1667-75. 2006
  10. ncbi request reprint Stability of irritable bowel syndrome using a Rome II-based classification
    R E Williams
    Worldwide Epidemiology, Glaxo SmithKline, Research Triangle Park, NC 27709, USA
    Aliment Pharmacol Ther 23:197-205. 2006

Collaborators

Detail Information

Publications17

  1. pmc Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
    Allen W Mangel
    RTI Health Solutions, Research Triangle Park, NC
    Clin Exp Gastroenterol 5:1-10. 2012
    ..Furthermore, the scientific rationale for the use of asimadoline in the treatment of IBS is reviewed. Considering the high patient and societal burdens of IBS, new treatments for IBS represent therapeutic advances...
  2. pmc Depolarization-stimulated contractility of gastrointestinal smooth muscle in calcium-free solution: a review
    Emily D Evans
    RTI Health Solutions, 3040 Cornwallis Drive, Research Triangle Park, NC 27709, USA
    ISRN Gastroenterol 2011:692528. 2011
    ..The present paper discusses the evidence in support of depolarization-mediated contractions occurring in gastrointestinal smooth muscle segments during incubation in solutions devoid of calcium...
  3. ncbi request reprint Clinical trials in irritable bowel syndrome: a review
    Claire M Ervin
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    Rev Recent Clin Trials 8:9-22. 2013
    ..In the present article we review publications reporting on phase 2 and phase 3 studies evaluating agents to potentially be used in the treatment of patients with IBS...
  4. doi request reprint Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome
    A W Mangel
    RTI Health Solutions, Research Triangle Park, NC, USA
    Aliment Pharmacol Ther 28:239-49. 2008
    ..In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function...
  5. doi request reprint Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients
    Allen W Mangel
    RTI Health Solutions, Research Triangle Park, N C 27709, USA
    Digestion 78:180-6. 2008
    ..Crofelemer improves bowel function in several conditions characterized by states of prominent secretory diarrhea...
  6. doi request reprint Asimadoline in the treatment of irritable bowel syndrome
    Allen W Mangel
    RTI Health Solutions NC 27709, USA
    Expert Opin Investig Drugs 19:1257-64. 2010
    ..Take home message: In a prospectively defined, clinically relevant patient subgroup, asimadoline shows efficacy in the treatment of D-IBS...
  7. ncbi request reprint Personal view: adequate relief as a primary endpoint in irritable bowel syndrome
    A W Mangel
    Research Triangle Institute Health Solutions, Research Triangle Park, NC 27709, USA
    Aliment Pharmacol Ther 23:879-81. 2006
    ..Adequate relief should be considered an acceptable primary endpoint by regulatory agencies for use in clinical trials of novel therapeutic agents for irritable bowel syndrome...
  8. doi request reprint Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists
    A W Mangel
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Neurogastroenterol Motil 20:1086-93. 2008
    ..These advances are illustrated by a review of trials with kappa opioid agonists and atypical benzodiazepine antagonists, which appear to be promising new classes of treatments for symptoms in IBS...
  9. ncbi request reprint Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome
    R E Williams
    Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC 27709 3395, USA
    Aliment Pharmacol Ther 23:1667-75. 2006
    ..Doctor visits for irritable bowel syndrome are associated with high medical costs. Predictors of medical consultation for irritable bowel syndrome remain poorly understood...
  10. ncbi request reprint Stability of irritable bowel syndrome using a Rome II-based classification
    R E Williams
    Worldwide Epidemiology, Glaxo SmithKline, Research Triangle Park, NC 27709, USA
    Aliment Pharmacol Ther 23:197-205. 2006
    ..As there is no biological marker for irritable bowel syndrome, a diagnosis is made using symptom-based criteria...
  11. doi request reprint Gastrointestinal side effects in chronic opioid users: results from a population-based survey
    S F Cook
    Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, USA
    Aliment Pharmacol Ther 27:1224-32. 2008
    ..Gastrointestinal side effects are commonly associated with opioid treatment for pain...
  12. ncbi request reprint Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome
    M E Watson
    Global Health Outcomes, Glaxo Wellcome, Research Triangle Park, North Carolina 27709-3398, USA
    Am J Gastroenterol 96:455-9. 2001
    ..CONCLUSIONS: These results in women with diarrhea-predominant IBS demonstrate that alosetron significantly improves health-related quality of life...
  13. ncbi request reprint Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey
    E B Andrews
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Aliment Pharmacol Ther 22:935-42. 2005
    ..Irritable bowel syndrome is a common gastrointestinal disorder, and its prevalence and demographics have been evaluated by different methodologies with varying results...
  14. ncbi request reprint Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome
    S M Leventer
    Vela Pharmaceuticals Inc, Ewing, NJ, USA
    Aliment Pharmacol Ther 27:197-206. 2008
    ..Dextofisopam modulates stimulated activity in animal models of stress, altered bowel motility, and visceral hypersensitivity...
  15. ncbi request reprint Study design issues in irritable bowel syndrome
    A W Mangel
    Aliment Pharmacol Ther 19:141-2. 2004
  16. ncbi request reprint A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia
    N J Talley
    Department of Medicine, University of Sydney, Sydney, Australia
    Aliment Pharmacol Ther 15:525-37. 2001
    ..Patients with adequate relief of upper abdominal pain or discomfort showed improvements in multiple functional dyspepsia symptoms...